Drugs / TRELANSERIN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00300339 | Feb 2006 → Dec 2007 | intermittent vascular claudication | Sanofi | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRELANSERIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3183740 ↗ |
| Known as | SL650472 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00300339 ↗ |
| Known as | Trelanserina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3183740 ↗ |
| Known as | Trelanserine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3183740 ↗ |
| Action | Inhibit | “Serotonin 1b (5-HT1b) receptor antagonist” CHEMBL3183740 ↗1“Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL3183740 ↗ |
| Modality | Small molecule | — CHEMBL3183740 ↗ |
| Target | HTR1B | “Serotonin 1b (5-HT1b) receptor antagonist” CHEMBL3183740 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL3183740 ↗ |